Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Short Interest Update

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) was the recipient of a large growth in short interest in December. As of December 31st, there was short interest totaling 115,672 shares, a growth of 32.9% from the December 15th total of 87,064 shares. Based on an average daily trading volume, of 217,009 shares, the days-to-cover ratio is presently 0.5 days. Currently, 0.1% of the company’s stock are sold short. Currently, 0.1% of the company’s stock are sold short. Based on an average daily trading volume, of 217,009 shares, the days-to-cover ratio is presently 0.5 days.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on IVA. UBS Group initiated coverage on Inventiva in a research report on Wednesday, January 7th. They set a “buy” rating and a $12.00 target price on the stock. Guggenheim decreased their price target on shares of Inventiva from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. Wall Street Zen upgraded shares of Inventiva to a “hold” rating in a research note on Saturday, October 18th. Leerink Partners started coverage on shares of Inventiva in a research report on Monday, January 12th. They issued an “outperform” rating and a $12.00 target price for the company. Finally, HC Wainwright upped their target price on shares of Inventiva from $20.00 to $24.00 and gave the company a “buy” rating in a research note on Thursday, October 9th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $16.00.

Institutional Investors Weigh In On Inventiva

Institutional investors and hedge funds have recently bought and sold shares of the business. Creative Planning bought a new position in Inventiva in the second quarter worth about $32,000. Wealth Enhancement Advisory Services LLC raised its position in shares of Inventiva by 54.5% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 16,558 shares of the company’s stock worth $50,000 after purchasing an additional 5,843 shares during the period. NewEdge Advisors LLC acquired a new stake in shares of Inventiva during the 3rd quarter worth approximately $116,000. Finally, Millennium Management LLC bought a new stake in shares of Inventiva in the 3rd quarter worth approximately $649,000. Institutional investors and hedge funds own 19.06% of the company’s stock.

Inventiva Stock Performance

IVA traded up $0.39 during trading hours on Monday, hitting $6.51. 387,465 shares of the stock were exchanged, compared to its average volume of 386,740. The stock has a 50-day simple moving average of $4.51 and a 200-day simple moving average of $4.58. Inventiva has a 12 month low of $2.11 and a 12 month high of $7.98.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.